Author:
Osaki Yui,Kawaratani Hideto,Kachi Hiroki,Matsuura Kyohei,Tsuji Yuki,Ozutsumi Takahiro,Takagi Hirotetsu,Furukawa Masanori,Sawada Yasuhiko,Mitoro Akira,Yamao Junichi,Yoshiji Hitoshi
Abstract
Abstract
Background
Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a rare but critical complication that develops in patients treated with MTX. Although MTX-LPD has been recently reported, the incidence of follicular lymphoma in the intestine is very low.
Case presentation
A 73-year-old woman who had been receiving MTX for over 10 years visited our hospital complaining of postprandial abdominal pain and nausea. Upper and lower digestive tract endoscopies did not show any abnormal findings. A patency capsule was stagnated at the proximal part of the ileum with a mild dilation on the oral side. An oral balloon endoscopy revealed shallow ulcerative lesions in the jejunum. She was diagnosed with MTX-LPD based on histopathological findings. The symptoms did not improve with the discontinuation of MTX, and the patient required partial resection of the small intestine. The test result for Epstein-Barr virus-encoded small RNA was negative. She was diagnosed with follicular lymphoma based on the histology findings of a surgical specimen. Postoperative positron emission tomography-computed tomography and bone marrow aspiration did not show any findings of lymphoma. On follow-up, no recurrence was noted four years after the surgery.
Conclusions
Herein, we report the first case of follicular lymphoma that occurred in the small intestine, negative for Epstein-Barr virus-encoded small RNA. If intestinal symptoms occur during MTX administration, it is important to directly observe by endoscopy and perform histological examination.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference15 articles.
1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–77.
2. Gaulard P, Swerdlow SH, Harris NL, et al. Other iatrogenic immunodeficiency associated lymphoproliferative disorders. In: WHO Classification of Tumors of the Haematopoietics and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp. 350–1.
3. Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019;59:72–92.
4. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82:1106–9.
5. Ishiguro K, Hayashi T, Aoki Y, Murakami R, Ikeda H, Ishida T. Other iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting as primary bone lymphoma in a patient with rheumatoid arthritis. Intern Med. 2016;55:2259–64.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献